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Abstract (limit 200) 
Acanthamoeba keratitis is caused by a protozoal infection of the cornea, with 80% of cases involving 
the improper use of contact lenses. The infection causes intense pain and is potentially blinding. 
However, early diagnosis improves treatment efficacy and the chances of healing. Despite the 
apparent accessibility of the cornea, patients do not always respond well to current eye drop 
treatments largely due to rapid dose loss due to blinking and nasolacrimal drainage. Here, the topical 
drug delivery of voriconazole alone and in combination with diclofenac via drug-loaded contact 
lenses, were investigated in vitro. The contact lenses were applied onto excised porcine eyeballs and 
maintained at 32 °C under constant irrigation, with simulated tear fluid applied to mimic in vivo 
conditions. The drug delivered to the corneas was quantified by HPLC analysis. The system was 
further tested in terms of cytotoxicity and a scratch wound repopulation model, using resident cell 
types. Sustained drug delivery to the cornea was achieved and for voriconazole, the MIC against 
Acanthamoeba castellanii was attained alone and in combination with diclofenac. MTT and scratch 
wound data showed reasonable cell proliferation and wound repopulation at the drug doses used, 
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1. Introduction 
 
Acanthamoeba keratitis (AK) is a serious, debilitating and potentially blinding inflammation of the 
cornea, caused by the infection of a free-living protozoan of the genus, Acanthamoeba. This amoeba 
resides in many environments including soil, air and water. The life cycle of Acanthamoeba includes 
two stages, an active trophozoite stage and a dormant cyst, both of which can be potentially 
pathogenic to humans (Clarke and Niederkorn, 2006). More than 80% of cases of this disease are 
found in contact lens wearers, since the wearing of contact lenses might facilitate the direct 
inoculation of the protozoan (Acanthamoeba Keratitis Fact Sheet for Healthcare Professionals, 
2017). The adherence of the trophozoite to the corneal epithelium is essential for producing the 
infection. The pathogenic cascade of AK begins when trophozoites bind to mannose glycoproteins of 
the corneal epithelium through mannose-binding protein on the trophozoite membrane. After binding 
occurs, trophozoite-mediated destruction of the corneal epithelium commences via several 
mechanisms, such as direct cytolysis, apoptosis and phagocytosis. The pathogenic cascade proceeds 
with the penetration of the Bowman’s membrane and the dissolution of the underlying collagenous 
stroma (Clarke and Niederkorn, 2006). An intense inflammation response is also a common sign of 
this pathology, with patients having very reddened eyes. In many cases, there is a loss of stromal 
keratocytes, infiltration of leukocytes, vascular congestion and chronic inflammation of the 
perilimbal bulbar conjunctiva (Garner, 1993). This amoeba also causes other symptoms, including 
foreign body sensation, decreased visual activity, photophobia and tearing. Early signs of AK may be 
mild and non-specific, with possible findings including epithelial irregularities, epithelial or stromal 
ulceration and infiltrates known as pseudodendrites. Later signs include stromal infiltrates, satellite 
lesions, radial keratoneuritis, scleritis and anterior uveitis. Advanced signs include stromal thinning 
and corneal perforation (Bernfeld et al., 2014).  
 
To achieve successful treatment of AK, early diagnosis and aggressive medical therapies are critical. 
Currently, the treatment of this disease involves topical eye drop delivery of a combination of 
antimicrobial membrane-acting agents such as chlorhexidine (0.2%), which at minimal 
concentrations is not toxic to corneal epithelial cells (Lim et al., 2008; Ferrari et al., 2011, Itahashi et 
al., 2011), with polyhexamethylene biguanide (PHMB), which is effective at low concentrations 
(0.02%) but is unfortunately toxic to human corneal keratocytes (Lee et al., 2007), brolene or 
hexamidine. Eye drops containing these agents must be administered hourly during waking hours for 
3 days; and then every 3 h for the following 3-4 weeks (Haburchak, 2017). However, 10% of the 
patients are resistant to treatment with chlorhexidine, in which case a combination of other 
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antimicrobial drugs should be used. The main drugs used are amphotericin B, rifampicin, 
pentamidine, flucytosine, pyrimethamine and cotrimoxazole. Even azole antifungal drugs, such as 
ketoconazole, voriconazole or clotrimazole, can be used orally or topically. The concomitant use of 
anti-inflammatory corticosteroids or NSAIDs is controversial and most authorities recommend it only 
when anterior-chamber inflammation is present. However, the biggest problem for the treatment of 
AK is the poor penetration of drugs into the stroma, the site of infection. Despite the easy accessibility 
of the eye for administering medications, the structure of the eye is very complicated, whilst the drugs 
used for the treatment of this disease are often molecules with high molecular weights and poor water 
solubility. This poses a significant challenge, in terms of their passage through the ocular barriers to 
the stroma. The main routes for administration of ophthalmic formulations are systemic, intravitreal 
and topical drug delivery. Systemic drug delivery needs high drug concentrations in the blood plasma, 
and this often exposes the patient to undesirable side effects. Instead, intraocular drug delivery by 
intravitreal injection is very effective in getting drugs to the posterior segment of the eye but is an 
invasive procedure with low patient compliance. Lastly, topical drug delivery is the most accepted 
route, as the solutions are relatively simply to formulate and there is high compliance from patients. 
However, traditional eyes drops are diluted in the tear film, eliminated quickly by the action of 
blinking and washed out by tears and nasolacrimal drainage. After instillation, only 1% or less of the 
drug reaches the target, the rest will be systemically adsorbed by the conjunctiva or nasolacrimal 
mucosa. Therapeutic contact lenses have been proposed as an ocular drug delivery mechanism that 
can overcome the limitations associated with conventional routes. Contact lenses are easy to 
administer and do not interfere with vision or normal eye functioning. They also offer controlled and 
sustained delivery of ocular drugs due to their unique properties of extended wear and more than 50% 
bioavailability in comparison to eye drop formulations (Li and Chauhan, 2006; Peng et al., 2010, 
2012; González-Chomón et al., 2013). Release of drugs from therapeutic contact lenses occurs in the 
pre- and post-lens tear film, which leads to a residence time of more than 30 minutes, compared to 
just 1-3 minutes for eye drop formulations (Mcnamara et al., 1999; Creech et al., 2001). The high 
drug residence time increases the bioavailability up to 50%, which ultimately reduces the dose, dosing 
frequency, systemic drug absorption and its associated side effects (Jain, 1988; Li and Chauhan, 2006; 
Li and Chauhan, 2007; Xinming et al., 2008). 
 
The drugs of choice in this work were voriconazole and diclofenac. Voriconazole is an 
antifungal drug that belongs to the triazole group. It acts by binding to the cytochrome P-450 enzyme 
lanosterol 14-α-demethylase, which is essential for the fungal cell membrane. It results in an alteration 
of the cell membrane and an enhanced permeability that causes cell dysfunction and a halt in growth 
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(Lin et al., 2013). Voriconazole is used for the treatment of invasive aspergillosis, for serious 
Scedosporum spp. or Fusarium spp. infections and for severe and fluconazole-resistant Candida spp. 
infections. It is also used for immunocompromised patients with life-threatening infections. This drug 
is administered via oral and intravenous routes; being available in the form of tablets, oral suspension 
and powder for solution infusion. Voriconazole is a lipophilic compound with low solubility (0.061% 
at pH 7), and is unstable in aqueous environments (Davies, 2000; Silveira, 2007). Whilst lipophilic 
compounds like voriconazole have higher corneal permeability, they usually have limited aqueous 
solubility. As such, formulating drug solutions can be challenging (Davies, 2000). For the formulation 
of a voriconazole drug solution to be feasible, the compound must be complexed with a β-
cyclodextrin derivative. Cyclodextrins are a group of homologous cyclic oligosaccharides that, in 
complex formation with a drug, increase dissolution rate (solubility), aqueous stability, and/or 
bioavailability of the drug (Järvinen et al., 1995). This increases the solubility and stability of 
voriconazole in aqueous solutions, while maintaining its lipophilicity and high corneal permeability 
(Järvinen et al., 1995; Davies, 2000). The secondary drug, diclofenac sodium is the sodium salt of 
diclofenac, a non-steroidal anti-inflammatory agents (NSAID), with a mechanism of action involving 
non-selective reversible and competitive inhibition of the enzyme cyclooxygenase (COX). The 
blockade of COX inhibits the conversion of arachidonic acid into prostaglandins involved in pain, 
inflammation and fever. For this reason, it has been used for a long time in the treatment of diseases 
due to a downregulation of the inflammatory cascade. Diclofenac is currently indicated for 
inflammatory based eye conditions, usually used as 0.1% eye drops (Diclofenac Sodium, 2018). For 
the treatment of AK, it could be used in combination with an amoebicidal drug, such as voriconazole, 
to reduce pain and inflammation in the cornea. 
 
Voriconazole has been investigated for its amoebicidal activity against Acanthamoeba 
castellanii and Acanthamoeba polyphaga, which are the most common species to cause keratitis (Dart 
et al., 2009). It was shown that it is a strong inhibitor of AcCYP51 activity and an effective inhibitor 
of trophozoite proliferation in vitro (Lamb et al., 2015). Recently, voriconazole has been successfully 
used both topically and systemically in human AK cases (Bang et al., 2010; Tu et al., 2010; Arnalich-
Montiel et al., 2012; Cabello-Vilchez et al., 2014). It has been reported in a case report that 1% topical 
voriconazole was effective in the treatment of two in three eyes affected by AK, but resistant to 
chlorhexidine treatment (Bang et al.,  2010). Although voriconazole can be considered a strong 
candidate for the treatment of human AK, it has been found in a study designed to investigate rat 
cornea penetration of eye drop and oral voriconazole that drug concentrations were directly dependent 
on the frequency of eye drop instillations, which resulted in lower plasma concentrations, whilst oral 
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voriconazole resulted in lower cornea concentrations (Gueudry et al., 2018). Also, despite 
voriconazole being inhibitory on clinical isolates of Acanthamoeba, amoebae have shown recovery 
from the effects of the drug upon transfer to a drug-free medium after a week or more (Schuster et 
al., 2006; Visvesvara et al., 2007). The results of these studies underline the need for high 
voriconazole corneal concentrations for efficient AK therapy, and the requirement for alternative 
routes of administration that achieve these concentrations whilst avoiding the use of high-frequency 
eye drop instillation regimens and high systemic doses of voriconazole. 
 
This study aimed to test the plausibility of topically delivering voriconazole and voriconazole 
plus diclofenac to the cornea using drug-loaded, hydrogel contact lenses and determine to what extent 
the drugs were released and delivered to the cornea in vitro compared to equivalent concentration eye 
drop formulations. 
 




Voriconazole was purchased from Acros Organics (Geel, Belgium). 2-hydroxypropyl-β-cyclodextrin 
(2-HP-β-CD) was purchased from Alfa Aesar (Poole, UK). HPLC grade water, HPLC grade 
methanol, HPLC grade acetonitrile, phosphate buffer saline (PBS) tablets, bovine serum albumin 
(BSA) and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific (Loughborough, UK). 
Diclofenac sodium salt, acetic acid, sodium chloride (NaCl), potassium chloride (KCl), calcium 
chloride (CaCl2) and sodium bicarbonate (NaHCO3) were purchased from Sigma-Aldrich Company 
Ltd (Poole, UK). ACUVUE TruEye contact lenses (46% water, 54% narafilcon A) were purchased 
from Johnson & Johnson Vision Care (Limerick, Ireland). Freshly excised porcine eyes were obtained 
from a local abattoir. Human corneal epithelial cells (HCE-2 [50.B1] ATCC® CRL-11135) were 
purchased from LGC Standards (Middlesex, UK). Keratinocyte serum-free media (KSFM) and 
bovine collagen type I was purchased from Gibco, (Paisley, UK). Human corneal keratocytes (HK), 
poly-L-lysine and fibroblast (FB) media were purchased from ScienCell (San Diego, CA, USA). 
Human fibronectin was purchased from Roche Diagnostics (Mannheim, Germany). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Tocris/Bio-
Techne (Bristol, UK). 
 
2.2. Preparation of solutions 
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A 1% w/v voriconazole solution was made by adding 500 mg of voriconazole to 50 mL of distilled 
deionised water. 8 g of 2-HP-β-CD was then slowly added to the solution under constant stirring; an 
ultrasonic water bath was also used to aid drug dissolution. ‘Eye drop’ formulations, containing the 
same concentrations of voriconazole and diclofenac absorbed by the contact lenses were used as 
comparators (Section 2.3.). A simple electrolyte-based simulated tear fluid (STF) was made by 
dissolving 6.7 g NaCl, 2.2 g NaHCO3, 0.61 g CaCl2 and 1.4 g KCl in 1 L distilled deionised water.  
 
2.3. Drug-loaded contact lenses 
 
The ‘breathing in’ technique was used to prepare drug-loaded contact lenses, whereby dehydrated 
lenses were placed in drug solution and allowed to imbibe drug whilst re-establishing normal 
hydration level. Firstly, 1-day Acuvue TruEye contact lenses were soaked in 20 mL of distilled 
deionised water for 3-4 h on a Cole-Parmer STR9 Gyro Rocker at room temperature to remove salts. 
The lenses were then dried in an oven at 60 °C for 1 h to remove all the moisture, and then weighed. 
The dried lenses were put in 10 mL of a 1% w/v voriconazole solution or 1% w/v voriconazole and 
0.5% w/v diclofenac and left overnight on a tube rotator at room temperature to allow rehydration 
and impregnation with the drug. The following day, lenses were carefully removed from the drug 
solution using forceps, gently dried on tissue paper and reweighed. The difference between the soaked 
weight and dried weight of the lenses is the amount of drug solution taken up, with the amount of 
drug absorbed by the lenses calculated based on the concentration of the solution of drug used.  
 
2.4. Drug release profile from contact lenses 
 
Hydrogel drug-loaded contact lenses were prepared, as described above. Each lens was put in a 
Falcon™ 15 mL centrifuge tube (Fisher Scientific UK Ltd, Loughborough, UK) containing 10 mL of 
distilled deionised water and left on a Cole-Parmer STR9 Gyro Rocker at room temperature. A 1 mL 
sample was taken after 10 min, 1 h, 2 h, 4 h and 6 h, and transferred to autosampler vials for analysis 
by HPLC, as described below. Following the 10 μL injection per time point, the 990 μL was 
retransferred to the Falcon™ 15 mL centrifuge tube. 
 
2.5. Drug delivery into porcine eyes 
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Porcine eyes were collected on the day of slaughter from a local abattoir, stored at 4 °C overnight and 
then used for experimentation within 12 h. Before experimentation, eyes were examined for abrasion 
or scarring, and any excess muscle and fat was removed using scissors. The eyes were put with cornea 
uppermost in individual wells of a 6-well plate containing 1 mL PBS, to prevent dehydration, and 
placed in a 37 °C water bath for 10 min. Subsequently, drug-loaded, contact lenses or 50 µL of 
equivalent concentration eye drops were applied. To mimic tear fluid, STF was dripped onto each 
eye using a 50 mL syringe driver with 12 tubes attached to bathe each eye, at a rate of 20 mL/h to 
simulate steady tear flow (Hewitt et al., in press). Eyes were left in the water bath for 2 h, 4 h or 6 h, 
to determine the kinetic release from the system and the penetration of the drug into the cornea. 
After each experiment, the eyes were taken out of the water bath and the contact lenses were removed. 
Using a scalpel and surgical scissors, each cornea was dissected and then extracted twice in methanol. 
Each cornea was placed in a 2 mL microcentrifuge tube with 1 mL of HPLC grade methanol, and put 
on a Fisher Scientific multi-purpose tube rotator at room temperature overnight. The following day 
each cornea was removed and placed in a second 2 mL microcentrifuge tube with 1 mL of fresh 
HPLC grade methanol; the previous methanol fraction was preserved in the fridge. The 
microcentrifuge tubes containing corneas were then put back on to the tube rotator again overnight. 
The following day the two methanol fractions were reunited into one microcentrifuge tube and left to 
evaporate overnight in a 60 °C oven. The methanol from both extraction steps were combined, 
centrifuged (3500 RPM) for 15 min and supernatants evaporated at 60 ºC overnight. The resulting 
residue was reconstituted with 1 mL fresh HPLC grade methanol and transferred to autosampler vials 
for HPLC. 
 
2.6. HPLC analysis 
 
HPLC was used to quantify drug release from the contact lenses and the amounts reaching the corneal 
stroma. For the quantitative analyses, an Agilent 1100 instrument fitted with a Phenomenex Kinetex 
5 µm C18 150 x 4.6 mm column was used. For voriconazole detection, a mobile phase composed of 
50% water and 50% acetonitrile was prepared. The UV detector was set at 256 nm, the injection 
volume was 10 µL, the flow rate was 1 mL/min and the run time was 6 min. A calibration curve was 
produced using standard solutions of voriconazole through a concentration range of 1.95-1000 
µg/mL; and the mean was R² = 0.9999. The retention time for the calibration curve and release profile 
was around 2.6 min, but with the corneas it was shifted to 1.55 min. For diclofenac detection, a mobile 
phase composed of 72% acetonitrile and 28% water was prepared, with the solution pH adjusted to 
3.5 using acetic acid. The UV detector was set at 280 nm, the injection volume was 10 µL, the flow 
International Journal of Pharmaceutics format 
   
  9 
rate was 1 mL/min and the run time was 5 min. The retention time was 1.9 min under these conditions. 
A calibration curve was produced using standard solutions of diclofenac through a concentration 
range of 1.95-1000 µg/mL and the mean was R² = 0.9992. 
 
2.7. Minimum inhibitory concentration (MIC) 
 
The MIC for voriconazole against Acanthamoeba castellanii was determined as described previously 
(Lamb et al., 2015) and found to be 0.5 µg/mL, which is reduced to 0.25 µg/mL when diclofenac is 
at 16 µg/mL or higher. For diclofenac, the MIC against Acanthamoeba castellanii is 128.0 µg/mL. 
All the data obtained in this study were expressed in average µg/cornea, for comparing with the MIC 
value they were converted to concentration values (µg/mL) using the following equation (Equation 
1): 





The volume of a standard porcine cornea was determined by measuring the wet and dry weights of 
porcine corneas (n=6) and then calculating the average total mass of water (g) within each specimen 
(wet weight (g) – dry weight (g) = total g of water). The total mass of water (g/cornea) is the 
equivalent of the amount of mL per cornea (mL/cornea), which was used in the equation above 
(Equation 1) for corneal volume. 
 
2.8. Cell viability evaluation 
 
An MTT assay was performed to assess the cytotoxicity of the voriconazole and/or diclofenac 
concentrations found by HPLC to be localized in porcine corneas 2 h, 4 h and 6 h post-application of 
the drug-loaded, contact lenses. Coated flat-bottomed, polystyrene 96-well plates were seeded with 
either 8,000 HCE-2 in 100 μL supplemented KSFM (well plates coated with 0.01 mg/mL BSA, 0.01 
mg/mL fibronectin and 0.03 mg/mL collagen type I in PBS) or 8,000 HK in 100 μL supplemented 
FB media (well plates coated with 2 μg/cm2 poly-L-lysine). Prepared plates were maintained at 37 °C 
in a humidified 5% CO2/95% air atmosphere for 24 h. Exposure to the test agents was initiated by 
adding the concentration of voriconazole and/or diclofenac (μg/mL) that corresponded to the amounts 
found to be localized following the use of contact lenses to three wells containing HCE-2/HK and 
three cell-free wells (per single or combination treatment) at the longest time-point (6 h exposure). 
This was repeated for the corresponding concentrations at each time point. For the untreated control 
wells, 10 μL of sterile HPLC grade water was added. Aliquots of MTT stock solution, previously 
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prepared in PBS and frozen at -20 °C, were thawed while protected from light. MTT stock solution 
was diluted in an uncoated 25 cm2 culture flask 1:5 with supplemented KSFM to a final concentration 
of 1 mg/mL and placed in the incubator to warm and equilibrate for 30-45 min before use. The relative 
number of viable cells was determined by adding diluted MTT solution for 2 h, followed by DMSO 
for 30 min. A Tecan Infinite M200 Pro Microplate Reader was used to measure the absorbance in 
each well at 506 nm, the λmax for the MTT formazan product formed, which was subsequently 
solubilized in 100 % DMSO. 
In order to interpret the raw MTT assay data, the absorbance readings of the cell-free wells 
(blanks) were firstly subtracted from each of their treated HCE-2/HK containing equivalents. Mean 
values for each technical triplicate were then calculated and the viability as a percentage of untreated 
controls were determined for each concentration of voriconazole and/or diclofenac using the 
following equation (Equation 2): 
 
% 𝑉𝑉𝑉𝑉𝑐𝑐𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 =
[𝐹𝐹𝐶𝐶𝑝𝑝𝑚𝑚𝑐𝑐𝐹𝐹𝑐𝑐𝐶𝐶 𝑐𝑐𝑉𝑉𝑎𝑎𝐶𝐶𝑝𝑝𝑉𝑉𝑐𝑐𝐶𝐶𝐶𝐶𝑝𝑝 𝑓𝑓𝑝𝑝𝐶𝐶𝑚𝑚 𝑉𝑉𝑝𝑝𝑝𝑝𝑐𝑐𝑉𝑉𝑝𝑝𝑡𝑡 𝐶𝐶𝑝𝑝𝑉𝑉𝑉𝑉𝑎𝑎]
[𝐹𝐹𝐶𝐶𝑝𝑝𝑚𝑚𝑐𝑐𝐹𝐹𝑐𝑐𝐶𝐶 𝑐𝑐𝑉𝑉𝑎𝑎𝐶𝐶𝑝𝑝𝑉𝑉𝑐𝑐𝐶𝐶𝐶𝐶𝑝𝑝 𝑓𝑓𝑝𝑝𝐶𝐶𝑚𝑚 𝑉𝑉𝑝𝑝𝑝𝑝𝑐𝑐𝑉𝑉𝑚𝑚𝑝𝑝𝐶𝐶𝑉𝑉 − 𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝 𝐶𝐶𝐶𝐶𝐶𝐶𝑉𝑉𝑝𝑝𝐶𝐶𝑉𝑉𝑎𝑎]
× 100 
 
2.9. Scratch wound assay using corneal epithelial cells 
 
The rate of wound closure in vitro was determined using Automated Confocal Time-Lapse 
Microscopy, based on the method of Hardwicke et al. (2010). HCE-2 cells were seeded into 24-well 
plates in KSFM and maintained at 37 °C in a humidified 5% CO2/95% air atmosphere, until confluent.  
Confluent HCE-2 monolayer cultures were scraped in a straight line with sterile p200 pipette tips to 
create a “scratch” wound, washed (x2) with PBS to remove debris and the KSFM replaced with 
treatment media containing the appropriate concentrations of voriconazole and/or diclofenac. 
Cultures were maintained at 37 °C in a humidified 5% CO2/95% air atmosphere, with the migration 
of cells into the denuded area monitored using the Leica TCS SP5 Confocal Microscope (Leica 
Microsystems, Milton Keynes, UK). Digital images were taken every 20 min over 6 h and converted 
to videos using LAS X Software (Leica Microsystems, Milton Keynes, UK). HCE-2 scratch wound 
repopulation rates were quantified using ImageJ® Software (Version 1.49, https://imagej.nih.gov/ij/), 
with data expressed as percentage wound closure at 2 h, 4 h and 6 h, versus wound areas at 0 h. 
Percentage wound closure rates were subsequently compared versus those of corresponding untreated 
control cultures. 
 
2.10. Data analysis 
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The data were analysed using Excel 2016 (Microsoft Office, Microsoft Corp., Redmon, WA, USA) 
and expressed as a mean ± SEM. Statistical analysis was carried out with InStat® for Macintosh, 
version 3.00 (GraphPad Software Inc., San Diego, CA, USA). The confidence interval was 95% and 
p <0.05 was considered to be significant. 
 
3. Results and Discussion 
 
AK is an increasingly widespread corneal disease of infectious origin caused by a free-living 
protozoan of the genus Acanthamoeba (Thebpatiphat et al., 2007). Although contact lens wear is the 
principle risk factor for the disease (Ibrahim et al., 2009), Acanthamoeba can also cause infection in 
non-contact lens wearers. A delay in diagnosing and treating AK can lead to significant loss of vision 
due to the destruction caused by the presence of the microorganism (Bacon et al., 1993). As 
Acanthamoeba infection increases in incidence, new therapies are required to overcome organisms 
that have become resistant to commonplace treatments. Furthermore, there are obstacles with ocular 
administration of medication, considering the physiological barriers of the eye, the unwanted side 
effects of systemic delivery and the invasive nature of intraocular methods. This study investigated 
the ex vivo use of anti-amoebic drug-loaded hydrogel contact lenses containing voriconazole alone or 
in combination with anti-inflammatory diclofenac on porcine corneas for the treatment of AK. 
The simplest way to load a drug into soft contact lenses is to soak preformed lenses in a 
solution of the drug. This technique relies on the passive diffusion of drug molecules into the lens 
matrix, but has the disadvantage of slow attainment of equilibrium, whereas the ‘breathing-in’ 
technique allows for much more rapid drug loading following lens rehydration (unpublished data). 
 
3.1. Drug release profile from contact lenses 
 
The percentage cumulative drug release profiles for the release of the drug(s) from single and binary-
loaded contact lenses were created in order to understand the kinetic release-rate of the drugs from 
the vehicle (Figures 1 and 2). An ideal kinetic release would be a zero-order model. Zero-order release 
kinetics describe systems where the drug release rate is constant over a period of time (Ciolino et al., 
2009). This allows the necessary concentration to be achieved quickly and be maintained throughout 
treatment duration. After ‘breathing-in’ 1% w/v voriconazole solution, hydrogel contact lenses 
absorbed 153.7 ± 6.7 µg voriconazole. The drug release profile (Figure 1) revealed that an average of 
14.0 ± 0.3 µg voriconazole was released after 10 min (9.1%), 21.1 ± 3.4 µg (22.9%) after 1 h, 23.4 ± 
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0.4 µg (38.1%) after 2 h, 24.7 ± 1.9 µg (54.2%) after 4 h; and 27.1 ± 2.7 µg (71.8%) after 6 h. When 
the hydrogel contact lenses ‘breathed in’ 1% w/v voriconazole and 0.5% w/v diclofenac solution, 
they absorbed 173.7 ± 17.9 µg voriconazole and 86.8 ± 8.9 µg diclofenac per contact lens. The drug 
release profile (Figure 2) revealed that after 10 min, an average of 4.1 ± 0.1 µg (2.3%) voriconazole 
and 10.6 ± 0.6 µg (12.3%) diclofenac were released, an average of 5.5 ± 0.7 µg (5.5%) voriconazole 
and 17.3 ± 1.4 µg (32.1%) diclofenac after 1 h, 7.5 ± 0.5 µg (9.8%) voriconazole and 19.0 ± 0.6 µg 
(54.0%) diclofenac after 2 h, 13.8 ± 1.4 µg (17.8%) voriconazole and 20.2 ± 0.6 µg (77.3%) 
diclofenac after 4 h; and an average of 19.3 ± 1.1 µg (28.9%) voriconazole and 17.8 ± 3.6 µg (97.8%) 
diclofenac after 6 h. For 1% w/v voriconazole-loaded contact lenses, there was a steady increase in 
drug release. Voriconazole is a lipophilic drug and the formulation required the inclusion of 2-HP-β-
CD as a solubilizer. The low water solubility and the presence of the cyclodextrin facilitate 
continuous, prolonged delivery of the drug to the cornea, without resulting in peaks of high drug 
concentration. The release of voriconazole from binary drug-loaded contact lenses was more gradual 
and resulted in lower drug release at each time point due to steric hinderance occurring between the 
voriconazole/2-HP-β-CD complex and the secondary drug, diclofenac. The binary loading of 
voriconazole/2-HP-β-CD and diclofenac could result in increased steric bulk within the confines of 
the polymeric network, resulting in slower drug release.  The release of diclofenac from the binary 
contact lenses was greater but still steady, obtaining a release percentage of 97.8% by 6 h. 
 
3.2. Comparing 1% w/v voriconazole-loaded contact lenses with equivalent concentration eye drops 
 
1% w/v voriconazole-loaded contact lenses were compared to 50 µL of an equivalent concentration 
eye drop formulation (Figure 3, Tables 1 and 2). After ‘breathing in’ 1% w/v voriconazole solution, 
the contact lenses absorbed an average of 157.7 ± 10.5 µg (n=9 ± SEM) voriconazole. The amount 
of drug delivered to the cornea was calculated as a percentage of the amount administered (n=3 
contact lenses) for the three corneas at each time point. After 2 h, the contact lenses delivered an 
average of 12.7 ± 0.3 µg (n=3 ± SEM) voriconazole to the cornea, equivalent to an average of 9.0 ± 
1.8%. After 4 h, the lenses delivered an average of 14.7 ± 1.1 µg (n=3 ± SEM) of drug per cornea, 
equivalent to an average of 8.3 ± 1.0% of the amount administered. Then, after 6 h, the lenses 
delivered an average of 7.3 ± 0.3 µg (n=3 ± SEM) voriconazole for each cornea, equal to an average 
of 5.2 ± 0.4% of the quantity absorbed. As a comparison, 50 µL of eye drop formulation containing 
155 µg voriconazole was used. Initially, after 2 h, the eye drops delivered an average of 6.0 ± 1.5 µg 
(n=3 ± SEM) of drug, equivalent to an average of 3.9 ± 1.0% of the amount administered. After 4 h, 
the eye drops delivered an average of 7.1 ± 1.1 µg (n=3 ± SEM) voriconazole, equal to an average of 
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4.6 ± 0.7% of the amount in the formulation. Then, after 6 h, equivalent concentration eye drops 
delivered an average of 5.3 ± 0.3 µg (n=3 ± SEM) voriconazole per cornea, equivalent to an average 
of 3.4 ± 0.2% of the amount administered. The concentration of voriconazole found to localise within 
the cornea following the application of voriconazole-only loaded contact lenses ranged between 38.5 
and 77.6 μg/ml through the time points. The concentration of voriconazole found to localise within 
the cornea following the application of voriconazole-only eye drops ranged between 27.8 and 37.4 
μg/ml through the time points. These concentration values align well with values found by a previous 
study conducted on rabbit corneas (Sun et al., 2008), which found that the drug concentration in the 
cornea following a single 50 μL dose of 1% voriconazole peaked at an average of 40 μg/ml. Therefore, 
1% w/v voriconazole-loaded, contact lenses delivered more voriconazole than equivalent 
concentration eye drops at each time-point, with these differences being significant at 2 h (p <0.001) 
and 4 h (p <0.001) post-treatment. 
 
3.3. Comparing 1% w/v voriconazole and 0.5% w/v diclofenac-loaded contact lenses with equivalent 
concentration eye drops 
 
1% w/v voriconazole and 0.5% w/v diclofenac-loaded contact lenses were compared to 50 µL of an 
equivalent concentration eye drop formulation (Figure 4, Tables 1 and 2). When allowed to ‘breathe 
in’ the solution overnight, the contact lenses absorbed an average of 189.9 ± 6.1 µg (n=9 ± SEM) 
voriconazole and 94.9 ± 3.1 µg (n=9 ± SEM) diclofenac. After 2 h, the contact lenses delivered an 
average of 11.7 ± 1.2 µg (n=3 ± SEM) voriconazole and 23.0 ± 5.1 µg (n=3 ± SEM) diclofenac per 
cornea. After 4 h, the lenses delivered an average of 15.4 ± 3.9 µg (n=3 ± SEM) voriconazole and 
27.8 ± 4.3 µg (n=3 ± SEM) diclofenac per cornea. Then, after 6 h, the lenses delivered an average of 
11.7 ± 1.8 µg (n=3 ± SEM) voriconazole and 23.4 ± 0.9 µg (n=3 ± SEM) diclofenac for each cornea. 
The amount of both drugs delivered to the cornea was again calculated as a percentage of the amount 
administered (n=3 contact lenses) for the three corneas at each time point. An average of 6.5 ± 0.8% 
voriconazole and 12.9 ± 1.6% diclofenac were delivered after 2 h from loaded contact lenses. After 
4 h, the lenses delivered an average of 8.1 ± 1.8% voriconazole and 16.1 ± 3.6% diclofenac of the 
amounts absorbed. Lastly, after 6 h, the contact lenses delivered an average of 6.0 ± 0.9% 
voriconazole and 12.0 ± 1.8% diclofenac of the amounts absorbed. After 2 h, equivalent concentration 
eye drops delivered an average of 3.4 ± 1.1 µg (n=3 ± SEM) voriconazole and 5.3 ± 1.7 µg (n=3 ± 
SEM) diclofenac per cornea. After 4 h, the eye drops delivered an average of 6.6 ± 1.4 µg (n=3 ± 
SEM) voriconazole and 4.9 ± 0.4 µg (n=3 ± SEM) diclofenac per cornea. Lastly, after 6 h, equivalent 
concentration eye drops delivered an average of 5.9 ± 1.1 µg (n=3 ± SEM) voriconazole and 4.9 ± 
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0.8 µg (n=3 ± SEM) diclofenac for each cornea. After 2 h, an average of 2.2 ± 0.7% voriconazole and 
3.0 ± 0.9% diclofenac of the amounts present in the solution were delivered. After 4 h, an average of 
4.3 ± 0.9% voriconazole and 2.7 ± 0.2% diclofenac were delivered to the cornea. Then, after 6 hours 
an average of 3.8% ± 0.7% of voriconazole and 2.7 ± 0.4% diclofenac were delivered.  
 
The concentration of voriconazole found to localise within the cornea following the application of 
binary-loaded contact lenses ranged between 61.7 and 81.3 μg/ml through the time points. The 
concentration of voriconazole found to localise within the cornea following the application of 
equivalent concentration eye drops ranged between 17.7 and 35.0 μg/ml through the time points. As 
with the single drug-loaded contact lenses, binary drug-loaded contact lenses delivered more 
voriconazole than equivalent concentration eye drops at each time-point and the localised 
concentration of voriconazole following the application of equivalent concentration eye drops 
corroborates well with values found in previous studies (Sun et al., 2008). The differences between 
binary contact lenses and equivalent concentration eye drops were significant at 2 h (p <0.05), 4 h (p 
<0.01) and 6 h (p <0.05) post-treatment. Performance was further improved by loaded contact lenses 
compared to eye drops for the delivery of diclofenac, with significant differences at 2 h (p <0.01), 4 
h (p <0.01) and 6 h (p <0.01) post-treatment. The delivery of diclofenac was consistently lower in 
combination than when delivered alone.  
 
3.4. Effect of voriconazole and/or diclofenac on corneal keratocyte and epithelial cell survival 
 
To address whether the concentrations of voriconazole and/or diclofenac that localised within the 
stroma influenced resident cell survival, an MTT assay was used to examine cell viability. En route 
to the stroma, the delivered drugs would encounter both epithelial cells and stromal keratocytes. HCE-
2 and HK cells were treated with the appropriate concentrations of voriconazole and/or diclofenac in 
KSFM/FB media for each corresponding exposure time (Table 3). HCE-2 cell viability was shown 
to remain above 90% compared to untreated controls when exposed to voriconazole alone, whether 
for short (2 h, 67.1 μg/mL) or longer periods (6 h, 38.47 μg/mL). However, exposure to diclofenac 
alone appeared to have more of an impact on cell viability, with HCE-2 viability decreasing from 
82.7% after 2 h exposure (289.95 μg/mL) to 62.4% after 6 h exposure (369.47 μg/mL). HK viability 
was shown to remain above the viability of the untreated controls when exposed to voriconazole 
alone, whether for short (2 h, 67.1 μg/mL) or longer periods (6 h, 38.47 μg/mL). In fact, voriconazole 
appeared to have a positive effect on the cells, with higher drug concentrations resulting in greater 
HK viability than at lower concentrations, irrespective of exposure time. However, as with the HCE-
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2 cells, exposure to diclofenac alone appeared to have more of an impact on cell viability, with HK 
viability decreasing from 95.5% after 2 h exposure (289.95 μg/mL) to 91.7% after 6 h exposure 
(369.47 μg/mL). HCE-2 viability when voriconazole and diclofenac were used in combination ranged 
between 85.6-72.8%. HK viability when the drugs were used in combination decreased from above 
the viability of the untreated controls after 2 h exposure (61.84 μg/mL voriconazole and 121.1 μg/mL 
diclofenac) to 92% after 6 h exposure (61.68 μg/mL voriconazole and 123.32 μg/mL diclofenac). 
Both cell types maintained relatively high levels of viability when exposed to corresponding 
concentrations of voriconazole alone at all three time-points assessed (greater than 90%). This was 
particularly the case with the keratocytes, which were especially resistant to the induction of any 
cytotoxic effects. Previous work has shown that voriconazole below concentrations of 25 µg/mL has 
no cytotoxic effect on corneal epithelial cells after an exposure time of 24 h (Sobolewska et al., 2015). 
In the current work, epithelial cells were exposed to higher concentrations (up to ~78 µg/mL), but 
only for a quarter of the time. After 24 h, the equivalent concentration (within a range of 50-100 
µg/mL) resulted in percentage viability values between 73.8% (50 µg/mL) and 59.2% (100 µg/mL), 
compared to untreated controls (Sobolewska et al., 2015). With the use of shorter exposure times 
(<24 h) and at the localised drug concentrations, it is unlikely that the epithelial cells would 
experience any significant detrimental effects from voriconazole alone. Diclofenac displayed more 
cytotoxicity on both cell types, whether alone or in combination with voriconazole, again to a greater 
extent than epithelial cells. Lower concentrations of diclofenac were applied when in combination, 
as less of the drug was found to localise in the cornea under these conditions. However, the presence 
of diclofenac still had an impact on cell viability to some degree. 
 
3.5. Effect of voriconazole and/or diclofenac on corneal epithelial wound healing in vitro 
 
Early signs of AK include epithelial ulceration, thus a scratch wound repopulation assay was 
performed using a Leica TCS SP5 Confocal Microscope (Figure 5) to investigate the effects of the 
drugs on epithelial cell migration and repair. The localized concentrations of voriconazole alone 
significantly diminished the rates of wound closure by HCE-2 cells (3.8- and 2.3-fold respectively, 
Figure 5) compared to untreated controls, at 4 h (p <0.05) and 6 h (p <0.05). However, no significant 
differences in wound closure rates were identified between untreated and voriconazole-treated HCE-
2 cells at 2 h post-treatment (p >0.05).  The localised concentrations of diclofenac alone also 
significantly diminished wound closure rates by HCE-2 cells (2.0-, 4.3- and 84.4-fold respectively, 
Figure 5) versus untreated controls, at 2 h (p <0.05), 4 h (p <0.001) and 6 h (p <0.001).  Also, the 
localized concentrations of the drugs in combination significantly diminished the rates of wound 
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closure by HCE-2 cells (2.9-, 11.3- and 26.0-fold respectively, Figure 5) compared to untreated 
controls, at 2 h (p <0.05), 4 h (p <0.001) and 6 h (p <0.001). The cells failed to migrate into the wound 
at the same rate as untreated controls overall, which implies that the drugs inhibited the migration and 
proliferation of treated cells. Again, the effects on the cells were greater in the presence of diclofenac. 
These results suggest that although diclofenac has the effect of blocking the inflammatory cascade, 
this is at the cost of somewhat decreasing cellular viability and their reparative capabilities. Previous 
work has reported on the toxicity of diclofenac sodium, with the drug being linked to toxicity in renal 
cortex mitochondria (Uyemura et al., 1997), NSAID-associated keratolysis (O’Brien et al., 2001) and 
corneal melting after LASIK (Hsu et al., 2003). In addition, NSAIDs inhibit COX activity in the 
arachidonic acid cascade and diminish prostaglandin synthesis. Prostaglandins are necessary for 
protein and DNA synthesis in epithelial cells. Therefore, use of NSAIDs (particularly diclofenac 
sodium) may affect corneal epithelial wound healing (Hersh et al., 1990; Lindstrom, 2006). 
Diclofenac sodium has also been reported as causing significant delays in early wound healing in the 
scraped rabbit corneal epithelium and re-epithelialisation after penetrating keratoplasty (Hersh et al., 
1990). These previous findings could explain the impact on cellular viability and wound repopulation 
observed in this study. Nevertheless, it is important to note that the MIC for voriconazole necessary 
to inhibit visible growth of the infection, was achieved and exceeded using the drug-loaded, contact 
lenses, both when single- and binary-loaded at all time-points examined; whilst maintaining the 
viability and to a lesser extent, the functionality of resident cell types. 
 
Overall, the drug-loaded, contact lenses proved superior to equivalent concentration eye drops 
and were shown to obtain consistent and sustained drug delivery to the cornea. For voriconazole, the 
MIC against Acanthamoeba castellanii was attained and surpassed, both alone and in combination 
with diclofenac throughout the study period. The delivery methods described here were tested ex vivo 
on porcine eyes, with constant dropwise irrigation of the eye with STF to account for tear production 
and to mimic the natural environment of the eye in vivo (Hewitt et al., in press). However, the 
pathologic condition of AK can present many adverse changes in the eye that could influence drug 
delivery. The epithelium is often damaged by the parasite through ulceration, immune cells can be 
present at the surface; and pH and temperature can also differ as a result of the inflammatory response. 
These variations in conditions could modify the permeation of the drug through the corneal tissue and 
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The findings of this work indicate that topically delivered voriconazole via binary drug-loaded, 
hydrogel contact lenses is a plausible improvement upon other delivery methods for the treatment of 
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Legends to Figures 
 
Figure 1. Percentage cumulative drug release profile from 1% w/v voriconazole-loaded, contact 
lenses (n=3 ± SD) 
 
Figure 2. Percentage cumulative drug release profile from 1% w/v voriconazole and 0.5% w/v 
diclofenac-loaded, contact lenses (n=3 ± SD). 
 
Figure 3. Quantities of voriconazole delivered to the cornea by 1% w/v voriconazole-loaded, contact 
lenses and equivalent concentration eye drops after 2 h, 4 h and 6 h (n=3 ± SEM, *** = p <0.001). 
 
Figure 4. Quantities of voriconazole and diclofenac delivered to the cornea by 1% w/v voriconazole 
and 0.5% w/v diclofenac-loaded, contact lenses and equivalent concentration eye drops after 2 h, 4 h 
and 6 h (n=3 ± SEM, * = p <0.05, ** = p <0.01). 
 
Figure 5. Percentage wound closure rates for untreated, voriconazole and diclofenac-treated, HCE-2 
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Table 1. 1% w/v voriconazole and/or 0.5% w/v diclofenac-loaded contact lenses. The amount of drug found 









Voriconazole (2 h) 12.7 67.0 
0.5 Voriconazole (4 h) 14.7 77.6 
Voriconazole (6 h) 7.3 38.5 
Diclofenac (2 h) 55.1 289.9 
128.0 Diclofenac (4 h) 55.8 293.6 
Diclofenac (6 h) 70.2 369.5 
Voriconazole in combination (2 h) 11.8 61.8 
0.25 Voriconazole in combination (4 h) 15.4 81.3 
Voriconazole in combination (6 h) 11.7 61.7 
Diclofenac in combination (2 h) 23.0 121.1 
128.0 Diclofenac in combination (4 h) 27.8 146.1 
Diclofenac in combination (6 h) 23.4 123.3 
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Table 2. 1% w/v voriconazole and/or 0.5% w/v diclofenac eye drop formulations. The amount of drug found 









Voriconazole (2 h) 6.0 31.5 
0.5 Voriconazole (4 h) 7.1 37.4 
Voriconazole (6 h) 5.3 27.8 
Diclofenac (2 h) 23.4 123.0 
128.0 Diclofenac (4 h) 15.9 83.8 
Diclofenac (6 h) 10.5 55.1 
Voriconazole in combination (2 h) 3.4 17.7 
0.25 Voriconazole in combination (4 h) 6.6 35.0 
Voriconazole in combination (6 h) 5.9 30.8 
Diclofenac in combination (2 h) 5.3 28.0 
128.0 Diclofenac in combination (4 h) 4.9 25.8 
Diclofenac in combination (6 h) 4.9 25.9 
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Table 3. Concentrations of voriconazole and/or diclofenac localised in porcine corneas, as a function of drug 
exposure times and cell viability values. 
 







Voriconazole (2 h) 67. 0 106.7 95.4 
Voriconazole (4 h) 77.6 109.1 90.9 
Voriconazole (6 h) 38.5 102.2 94.7 
Diclofenac (2 h) 289.9 95.5 82.7 
Diclofenac (4 h) 293.6 93.7 74.1 
Diclofenac (6 h) 369.5 91.7 62.4 
Voriconazole in combination (2 h) 61.8 108.2 85.6 
Voriconazole in combination (4 h) 81.3 99.0 72.8 
Voriconazole in combination (6 h) 61.7 92.0 77.4 
Diclofenac in combination (2 h) 121.1 108.2 85.6 
Diclofenac in combination (4 h) 146.1 99.0 72.8 
Diclofenac in combination (6 h) 123.3 92.0 77.4 
 
